Growth hormone treatment in Turner syndrome: results of a multicentre study in Japan. The Committee for the Treatment of Turner Syndrome.
Patients with Turner syndrome were treated with recombinant human growth hormone (GH) for 3 years. Sixty-eight patients received GH, 0.5 IU/kg/week, while 93 received GH, 1.0 IU/kg/week, by daily subcutaneous injection. Both treatment groups showed a statistically significant increase in growth during treatment. However, the higher dose increased height velocity to a significantly greater extent during the first and second year of treatment. The projected adult height was exceeded by 52 of 71 patients over the age of 14 years. Plasma insulin-like growth factor 1 levels were elevated and no remarkable advances in bone age were observed. There were no other significant changes in physical or laboratory parameters. No glucose intolerance was observed. These results indicate that GH treatment is useful for accelerating growth velocity in patients with Turner syndrome. However, further study will be required to find the most appropriate dose.
Takano
K
K
Department of Medicine, Tokyo Women's Medical College, Japan.
Shizume
K
K
Hibi
I
I
Ogawa
M
M
Okada
Y
Y
Suwa
S
S
Tanaka
T
T
D000293:Adolescent; D001786:Blood Glucose / Q000032:analysis; D001827:Body Height / Q000187:drug effects*; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D005951:Glucose Tolerance Test; D006128:Growth / Q000187:drug effects*; D013006:Growth Hormone / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007564:Japan; D011627:Puberty / Q000187:drug effects; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D014424:Turner Syndrome / Q000188:drug therapy* / Q000503:physiopathology
D001786:Blood Glucose; D011994:Recombinant Proteins; D013006:Growth Hormone